{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T20:43:59Z","timestamp":1794689039246,"version":"4.9.1"},"reference-count":29,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Immune checkpoint inhibitor (ICI) combinations and tyrosine kinase inhibitor (TKI) use are standard for metastatic renal cell carcinoma (mRCC), leading to improved outcomes. However, due to a lack of predictive biomarkers, the presence or absence of immune-related adverse events (irAE) is currently used as a predictive factor in clinical practice. To elucidate the impact of irAEs on efficacy, a cohort of patients with mRCC who received ICI-based combination therapy as initial treatment was analyzed. Patients were divided into two groups: those who received dual-ICI therapy (ICI\u2013ICI, N = 55) or ICI and TKI therapy (ICI\u2013TKI, N = 55). Subsequent to this initial categorization, each group was further subdivided based on the presence or absence of irAEs. In the ICI\u2013ICI group, patients with irAEs exhibited significantly prolonged overall survival (OS) and progression-free survival [PFS; OS (median): not reached vs. 17.9 months, P = 0.03\/PFS (median): 51.4 vs. 5.8 months, P &amp;lt; 0.01]. Conversely, no such correlation was observed between irAEs and OS\/PFS in the ICI\u2013TKI group. [OS (median): 26.3 months vs. not reached, P = 0.73\/PFS (median): 16.8 months vs. 11.9 months, P = 0.38] Furthermore, treatment discontinuation due to AEs accounted for 65% (N = 32) in the ICI\u2013ICI group and 57% (N = 24) in the ICI\u2013TKI group, with a slightly higher tendency observed in the ICI\u2013ICI group. These findings suggest that the prognostic impact of irAEs may differ depending on the treatment combination, and further basic research is needed to elucidate the underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In patients with mRCC who received ICI\u2013ICI, the occurrence of irAEs was associated with improved survival outcomes, whereas no such association was observed in patients who received ICI\u2013TKI. This suggests that irAEs may reflect the favorable immune response specific to ICI\u2013ICI therapy, whereas differences in the tumor microenvironment, particularly involving neutrophils, in ICI\u2013TKI patients may influence treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0337","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T13:21:06Z","timestamp":1757078466000},"page":"1681-1689","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint\/Tyrosine Kinase Inhibition for Metastatic Renal Cancer"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6483-3032","authenticated-orcid":false,"given":"Bunpei","family":"Isoda","sequence":"first","affiliation":[{"name":"1Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8610-0149","authenticated-orcid":false,"given":"Masanobu","family":"Shiga","sequence":"additional","affiliation":[{"name":"1Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4621-8470","authenticated-orcid":false,"given":"Shuya","family":"Kandori","sequence":"additional","affiliation":[{"name":"1Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5673-3559","authenticated-orcid":false,"given":"Shota","family":"Takahashi","sequence":"additional","affiliation":[{"name":"1Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1397-9792","authenticated-orcid":false,"given":"Akifumi","family":"Omiya","sequence":"additional","affiliation":[{"name":"2Department of Urology, Ibaraki Prefectural Central Hospital, Kasama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1261-0766","authenticated-orcid":false,"given":"Tomoki","family":"Ishida","sequence":"additional","affiliation":[{"name":"2Department of Urology, Ibaraki Prefectural Central Hospital, Kasama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6941-0750","authenticated-orcid":false,"given":"Kotoe","family":"Matsuda","sequence":"additional","affiliation":[{"name":"3Department of Urology, Hitachi General Hospital, Hitachi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1254-0001","authenticated-orcid":false,"given":"Hiromichi","family":"Sakurai","sequence":"additional","affiliation":[{"name":"1Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9879-8289","authenticated-orcid":false,"given":"Bryan J.","family":"Mathis","sequence":"additional","affiliation":[{"name":"4Department of Cardiovascular Surgery, Institute of Medicine, University of Tsukuba, Tsukuba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4350-4156","authenticated-orcid":false,"given":"Ken","family":"Tanaka","sequence":"additional","affiliation":[{"name":"5Department of Urology, Tsukuba Medical Center Hospital, Tsukuba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5184-1250","authenticated-orcid":false,"given":"Manabu","family":"Komine","sequence":"additional","affiliation":[{"name":"5Department of Urology, Tsukuba Medical Center Hospital, Tsukuba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1777-1525","authenticated-orcid":false,"given":"Masahiro","family":"Iinuma","sequence":"additional","affiliation":[{"name":"6Department of Urology, National Hospital Organization Mito Medical Center, Mito, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8589-9737","authenticated-orcid":false,"given":"Akira","family":"Joraku","sequence":"additional","affiliation":[{"name":"2Department of Urology, Ibaraki Prefectural Central Hospital, Kasama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1144-2755","authenticated-orcid":false,"given":"Hiromitsu","family":"Negoro","sequence":"additional","affiliation":[{"name":"3Department of Urology, Hitachi General Hospital, Hitachi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6556-2862","authenticated-orcid":false,"given":"Masakazu","family":"Tsutsumi","sequence":"additional","affiliation":[{"name":"3Department of Urology, Hitachi General Hospital, Hitachi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1362-4344","authenticated-orcid":false,"given":"Takamitsu","family":"Inoue","sequence":"additional","affiliation":[{"name":"7Department of Urology, International University of Health and Welfare Narita Hospital, Narita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3618-0432","authenticated-orcid":false,"given":"Jun","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"7Department of Urology, International University of Health and Welfare Narita Hospital, Narita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-596X","authenticated-orcid":false,"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"1Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"2025091823542654100_bib1","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"key":"2025091823542654100_bib2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur Urol"},{"key":"2025091823542654100_bib3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"2025091823542654100_bib4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025091823542654100_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","article-title":"Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial","volume":"36","author":"Choueiri","year":"2025","journal-title":"Ann Oncol"},{"key":"2025091823542654100_bib6","doi-asserted-by":"crossref","first-page":"633032","DOI":"10.3389\/fonc.2021.633032","article-title":"Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis","volume":"11","author":"Fan","year":"2021","journal-title":"Front Oncol"},{"key":"2025091823542654100_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"2025091823542654100_bib8","doi-asserted-by":"crossref","first-page":"355.e21","DOI":"10.1016\/j.urolonc.2019.03.003","article-title":"Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab","volume":"37","author":"Ishihara","year":"2019","journal-title":"Urol Oncol"},{"key":"2025091823542654100_bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jjco\/hyac009","article-title":"Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab","volume":"52","author":"Ueda","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2025091823542654100_bib10","doi-asserted-by":"crossref","first-page":"16436","DOI":"10.1038\/s41598-021-95985-6","article-title":"Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations","volume":"11","author":"Nguyen","year":"2021","journal-title":"Sci Rep"},{"key":"2025091823542654100_bib11","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2025091823542654100_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"2025091823542654100_bib13","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"2025091823542654100_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025091823542654100_bib15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.euo.2023.01.010","article-title":"Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study","volume":"6","author":"Gr\u00fcnwald","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"2025091823542654100_bib16","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"2025091823542654100_bib17","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.3390\/ijms25137444","article-title":"TNFSF9 is associated with favorable tumor immune microenvironment in patients with renal cell carcinoma who are treated with the combination therapy of nivolumab and ipilimumab","volume":"25","author":"Isoda","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025091823542654100_bib18","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1084\/jem.156.6.1755","article-title":"Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets","volume":"156","author":"Houghton","year":"1982","journal-title":"J Exp Med"},{"key":"2025091823542654100_bib19","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/archderm.1995.01690150078015","article-title":"Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells","volume":"131","author":"Cui","year":"1995","journal-title":"Arch Dermatol"},{"key":"2025091823542654100_bib20","doi-asserted-by":"crossref","first-page":"e1386362","DOI":"10.1080\/2162402X.2017.1386362","article-title":"The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors","volume":"7","author":"L\u00e4ubli","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025091823542654100_bib21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature07662","article-title":"Enhancing SIV-specific immunity in vivo by PD-1 blockade","volume":"458","author":"Velu","year":"2009","journal-title":"Nature"},{"key":"2025091823542654100_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"key":"2025091823542654100_bib23","doi-asserted-by":"crossref","first-page":"15585","DOI":"10.3390\/ijms232415585","article-title":"The VEGF\/VEGFR axis revisited: implications for cancer therapy","volume":"23","author":"Mabeta","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025091823542654100_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00018-023-04729-4","article-title":"Receptor tyrosine kinase inhibitors in cancer","volume":"80","author":"Ebrahimi","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"2025091823542654100_bib25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr Drug Metab"},{"key":"2025091823542654100_bib26","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2326-6066.CIR-21-1039","article-title":"Tyrosine kinase inhibition alters intratumoral CD8+ T-cell subtype composition and activity","volume":"10","author":"Tieniber","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2025091823542654100_bib27","doi-asserted-by":"crossref","first-page":"858","DOI":"10.20517\/cdr.2023.89","article-title":"Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma","volume":"6","author":"Sweeney","year":"2023","journal-title":"Cancer Drug Resist"},{"key":"2025091823542654100_bib28","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1158\/1078-0432.CCR-21-2517","article-title":"Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma","volume":"28","author":"Esteban-Fabr\u00f3","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025091823542654100_bib29","doi-asserted-by":"crossref","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology (Oxford)"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0337\/3648418\/crc-25-0337.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1681\/3651807\/crc-25-0337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1681\/3651807\/crc-25-0337.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T03:54:36Z","timestamp":1758254076000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/9\/1681\/765358\/Prognostic-Impact-of-Immune-Related-Adverse-Events"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0337","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30162532","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30162553","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30162541","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30162550","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30162529","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30162547","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30162535","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30162544","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8043424","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}